Wegovy for PCOS: Evidence, Eligibility, Coverage
Wegovy is not FDA approved for polycystic ovary syndrome (PCOS). It is approved for weight loss, heart risk and MASH liver disease. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.
- Active ingredient
- semaglutide
- How it is taken
- weekly injection or daily tablet
- Approved for
- Weight loss, heart risk and MASH liver disease
- Best result (STEP 1)
- 14.9% weight loss
Wegovy overview
Its half-life is about 1 week: after 7 d, half is gone, and after five half-lives (35 d), about 3% is left.
STEP 1 at 68 weeks showed 14.9% of body weight, compared with 2.4% on placebo.
Monthly prices in US dollars include the list price and self-pay offers. Each one comes from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.
Who qualifies?
| Who sets the rule | Who qualifies |
|---|---|
| FDA label | For adults with heart disease and obesity or overweight, this medicine lowers the risk of a heart attack, stroke, or heart-related death. Both injection and tablets have this effect. |
| FDA label | It supports long-term weight loss and helps keep it off when used with diet and activity. This applies to adults and children 12 and older with obesity, and to adults with overweight and a weight-related condition. |
| FDA label | In adults, it treats MASH liver disease with moderate to advanced scarring (no cirrhosis) (injection). |
| FDA label | For adults, the tablets are approved for weight loss and heart risk. |
| Medicare GLP-1 Bridge | BMI 35 or higher, no condition needed |
| Medicare GLP-1 Bridge | A BMI of 30 or higher is required, along with heart failure, uncontrolled blood pressure, or CKD 3a+ |
| Medicare GLP-1 Bridge | BMI 27 or higher, along with prediabetes, a past heart attack or stroke, or PAD |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | a diet and activity program that lasts 6 months comes first |
Sources: FDA label (DailyMed), medicare.gov 1 2, aetna.com.
PCOS trial findings
No trial enrolled only people with polycystic ovary syndrome (PCOS); all participants were adults with obesity or overweight and did not have diabetes.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| STEP 1 | Wegovy | Adults with obesity or overweight, without diabetes | 68 weeks | 1,961 | 14.9% weight loss | 2.4% on placebo |
| OASIS 4 | Wegovy | Adults with obesity or overweight, without diabetes | 64 weeks | 307 | 13.6% weight loss | 2.4% on placebo |
Source of the trial: STEP 1 (FDA label (DailyMed)).
What is different for PCOS?
| What changes | What the label says |
|---|---|
| Hypoglycemia | Using it with insulin or a sulfonylurea increases the chance of low blood sugar, so those doses may need to be lowered. |
These facts come from the FDA labels: DailyMed FDA label.
These warnings come from the FDA DailyMed label.
Coverage for PCOS
For a GLP-1 used only for weight loss, Medicare Part D will not pay.
Wegovy is listed on the Medicare GLP-1 Bridge for $50 each month, and you must meet its rules
When Medicaid covers weight-loss GLP-1s, prior authorization is standard.
Sources: CMS, KFF, humana.com.
- Wegovy Coupon and Savings Card
- Wegovy Cost
- Wegovy Cost Without Insurance
- Wegovy Cost With Insurance
- Cheapest Way to Get Wegovy
- Wegovy Patient Assistance
- Is Wegovy Covered by Insurance? Criteria, Copay, Appeal
- Does Medicare Cover Wegovy? Criteria, Copay, How to Appeal
- Does BCBS Cover Wegovy? Coverage by State Plan, PA Rules, Appeals
Alternatives for PCOS
| Medicine | For PCOS | How it is taken | Trial result |
|---|---|---|---|
| Wegovy | Not a listed use | weekly injection or daily tablet | 14.9% weight loss |
 Ozempic | Not a listed use | weekly injection | Not listed |
 Rybelsus | Not a listed use | daily tablet | Not listed |
 Mounjaro | Not a listed use | weekly injection | Not listed |
 Zepbound | Not a listed use | weekly injection | 20.9% weight loss |
 Foundayo | Not a listed use | daily tablet | 11.1% weight loss |
 Trulicity | Not a listed use | weekly injection | Not listed |
 Saxenda | Not a listed use | daily injection | 7.4% weight loss |
 Victoza | Not a listed use | daily injection | Not listed |
| Byetta | Not a listed use | twice-daily injection | Not listed |
Reference: FDA DailyMed label.
Your prescriber: questions to ask
- Will this have any effect on my birth control?
- When should I stop before trying to get pregnant?
- Will my plan probably cover this when PCOS is the main reason?
Read the full DailyMed Wegovy prescribing information.